Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ondine Biomedical, Inc. ( (GB:OBI) ) just unveiled an update.
Ondine Biomedical Inc. has announced that Cambie Surgery Centre, a leading private surgical facility in Canada, has adopted Ondine’s Steriwave® nasal photodisinfection as the standard of care for orthopedic and plastic surgeries. This decision marks a significant step in addressing the challenge of surgical site infections and antibiotic resistance, as Steriwave offers a rapid, broad-spectrum antimicrobial solution without fostering resistance. The adoption by Cambie Surgery Centre, known for its excellence in patient care, underscores a growing trend among Canadian surgical facilities to enhance infection prevention protocols, potentially setting new benchmarks for surgical safety in the country.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, for preventing and treating infections, including those caused by multidrug-resistant organisms. The company has a range of investigational products based on its proprietary technology and its nasal photodisinfection system, Steriwave®, is approved in several countries and undergoing clinical trials in the US.
Average Trading Volume: 174,536
Technical Sentiment Signal: Buy
Current Market Cap: £63.16M
Find detailed analytics on OBI stock on TipRanks’ Stock Analysis page.